JP2020504093A - 天然配合ホルモン補充製剤及び治療法 - Google Patents

天然配合ホルモン補充製剤及び治療法 Download PDF

Info

Publication number
JP2020504093A
JP2020504093A JP2019530027A JP2019530027A JP2020504093A JP 2020504093 A JP2020504093 A JP 2020504093A JP 2019530027 A JP2019530027 A JP 2019530027A JP 2019530027 A JP2019530027 A JP 2019530027A JP 2020504093 A JP2020504093 A JP 2020504093A
Authority
JP
Japan
Prior art keywords
estradiol
subject
progesterone
max
auc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504093A5 (cg-RX-API-DMAC10.html
Inventor
エム アマディオ ジュリア
エム アマディオ ジュリア
エイ バーニック ブライアン
エイ バーニック ブライアン
マーキン セバスチャン
マーキン セバスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TherapeuticsMD Inc
Original Assignee
TherapeuticsMD Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TherapeuticsMD Inc filed Critical TherapeuticsMD Inc
Publication of JP2020504093A publication Critical patent/JP2020504093A/ja
Publication of JP2020504093A5 publication Critical patent/JP2020504093A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019530027A 2016-12-05 2017-12-05 天然配合ホルモン補充製剤及び治療法 Pending JP2020504093A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430339P 2016-12-05 2016-12-05
US62/430,339 2016-12-05
US201762481060P 2017-04-03 2017-04-03
US62/481,060 2017-04-03
PCT/US2017/064788 WO2018136161A1 (en) 2016-12-05 2017-12-05 Natural combination hormone replacement formulations and therapies

Publications (2)

Publication Number Publication Date
JP2020504093A true JP2020504093A (ja) 2020-02-06
JP2020504093A5 JP2020504093A5 (cg-RX-API-DMAC10.html) 2021-01-28

Family

ID=62908279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019530027A Pending JP2020504093A (ja) 2016-12-05 2017-12-05 天然配合ホルモン補充製剤及び治療法

Country Status (11)

Country Link
EP (1) EP3548036A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020504093A (cg-RX-API-DMAC10.html)
KR (1) KR20200018383A (cg-RX-API-DMAC10.html)
CN (1) CN110290793A (cg-RX-API-DMAC10.html)
AU (1) AU2017394679A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019011655A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045024A1 (cg-RX-API-DMAC10.html)
IL (1) IL267023A (cg-RX-API-DMAC10.html)
MX (1) MX2019006513A (cg-RX-API-DMAC10.html)
RU (1) RU2019115913A (cg-RX-API-DMAC10.html)
WO (1) WO2018136161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd
GB202316026D0 (en) * 2023-10-19 2023-12-06 Theramex Hq Uk Ltd Methods of prevention or treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150342963A1 (en) * 2014-05-22 2015-12-03 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US6901278B1 (en) * 2002-01-29 2005-05-31 Morris Notelovitz Methods for reducing the risk of breast cancer in and improving the health of women
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150342963A1 (en) * 2014-05-22 2015-12-03 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MATURITAS, vol. 81, no. 1, JPN6021044382, 2015, pages 28 - 35, ISSN: 0004792719 *
PHARMA MEDICA, vol. 22, no. 4, JPN6022022327, 2004, pages 33 - 37, ISSN: 0004792721 *
臨床医薬, vol. 12巻，18号, JPN6022022326, 1996, pages 171 - 195, ISSN: 0004792720 *

Also Published As

Publication number Publication date
IL267023A (en) 2019-07-31
RU2019115913A (ru) 2021-01-15
AU2017394679A1 (en) 2019-06-13
WO2018136161A1 (en) 2018-07-26
WO2018136161A9 (en) 2019-08-22
EP3548036A4 (en) 2020-06-17
RU2019115913A3 (cg-RX-API-DMAC10.html) 2021-03-19
KR20200018383A (ko) 2020-02-19
MX2019006513A (es) 2019-08-14
CN110290793A (zh) 2019-09-27
BR112019011655A2 (pt) 2019-10-22
EP3548036A1 (en) 2019-10-09
CA3045024A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
US20180221389A1 (en) Natural combination hormone replacement formulations and therapies
Sibai et al. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra™/Evra™)
Jayasena et al. A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women
Murphy et al. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding
Ruggiero et al. Estrogen: physiology, pharmacology, and formulations for replacement therapy
JP5762390B2 (ja) 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
US20190247401A1 (en) Natural combination hormone replacement formulations and therapies
Simon et al. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms
Winkler et al. The effects of two monophasic oral contraceptives containing 30 mcg of ethinyl estradiol and either 2 mg of chlormadinone acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic parameters
Johansson et al. Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy women
JP2003505345A (ja) 女性への非経口アンドロゲンステロイドの投与
Jensen Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest
Momoeda et al. Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
Guay Decreased testosterone in regularly menstruating women with decreased libido: a clinical observation
KR20170005819A (ko) 천연 복합 호르몬 대체 제형 및 요법
Sood et al. Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial
JP6562630B2 (ja) 経鼻投与用の低投薬濃度テストステロンゲル製剤および無オルガズム症または性的欲求低下障害を治療するためのその使用
Gast et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women
Hedrick et al. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women
Buster Transdermal menopausal hormone therapy: delivery through skin changes the rules
Looby et al. Effects of long-term testosterone administration in HIV-infected women: a randomized, placebo-controlled trial
KR20200018383A (ko) 천연 복합 호르몬 대체 제형 및 요법
Akintomide et al. Nomegestrol acetate/17-beta estradiol: a review of efficacy, safety, and patient acceptability
Palacios et al. POESIT recommendations on management of body-identical hormones in menopausal symptoms
US20230302015A1 (en) Natural combination hormone replacement formulations and therapies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220210

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220607